The high-level expression of EpCAM in various carcinomas (e.g. prostate, ovarian, lung, colon, and breast cancers) and metastases, along with its correlation to clinical outcomes, has established it as both a prognostic marker and a therapeutic target (Went et al. 2006). This evidence concerns the gene EPCAM and carcinoma.